Peter Loftus

Lipfendra, to be taken once a day, is designed to help lower cholesterol levels beyond what statins alone can achieve.

The market leader in obesity shots, Lilly hasn’t made a major dent in the pill market yet.

Millions of older Americans are on the cusp of more affordable access to popular weight-loss drugs when a major Medicare coverage expansion kicks in July 1.

The cash deal will add an experimental drug for moderate to severe atopic dermatitis, building up AbbVie’s core business.

After shedding its oncology business just over a decade ago, GSK is building it back with a $10.6 billion deal.

More employers are requiring weigh-ins, app tracking and health coaching before approving GLP-1s for losing weight—or dropping coverage altogether.

The “M*A*S*H” star’s program to help researchers overcome their communication challenges now draws thousands. We sat in on a class.

Some promising candidates are sitting on the shelf, awaiting funds before human tests.

Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.

Drug companies like Eli Lilly and Roche are racing to build supercomputers to help fix the 90% failure rate in drug development.